Their origin and how they transform cholesterol, phospholipids, plasmalogens, polyunsaturated fatty acids, sugars, and proteins into deleterious products. Free Radic

Biol Med 2006, 41:362–387.PubMedCrossRef 10. Mrak RE, Landreth GE: PPARgamma, neuroinflammation, and disease. J Neuroinflammation 2004, 1:5.PubMedCrossRef 11. Sumariwalla PF, Palmer CD, Pickford LB, Feldmann M, Foxwell BM, Brennan FM: Suppression AR-13324 clinical trial of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717. Rheumatology (Oxford) 2009, 48:32–38.CrossRef 12. Simmonds RE, Foxwell BM: Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:584–590.CrossRef 13. Jin JQ, Li CQ, He LC: Down-regulatory effect of usnic acid on nuclear factor-kappaB-dependent tumor necrosis JIB04 factor-alpha and inducible nitric oxide synthase expression in lipopolysaccharide-stimulated macrophages RAW 264.7. Phytother Res 2008, 22:1605–1609.PubMedCrossRef 14. Yun KJ, Koh DJ, Kim SH, Park SJ, Ryu JH, Kim DG, Lee JY, Lee KT: Anti-inflammatory BTK phosphorylation effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygase-2, and proinflammatory cytokines expressions via nuclear factor-kappaB inactivation. J Agric Food Chem

2008, 56:10265–10272.PubMedCrossRef 15. Nakanishi Y, Kamijo R, Takizawa K, Hatori M, Nagumo M: Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur J Cancer 2001, 37:1570–1578.PubMedCrossRef 16. Jobin C, Morteau O, Han DS, Balfour Sartor R: Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 1998, 95:537–543.PubMedCrossRef 17. Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y,

Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 2010, 8:13.PubMedCrossRef 18. Ritchie SA, Heath D, Yamazaki Y, Grimmalt B, Tau-protein kinase Kavianpour A, Krenitsky K, Elshoni H, Takemasa I, Miyake M, Sekimoto M, Monden M, Tomonaga T, Matsubara H, Sogawa K, Matsushita K, Nomura F, Goodenowe DB: Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol 2010, 10:140.PubMedCrossRef 19. Davies GF, Roesler WJ, Juurlink BH, Harkness TA: Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma 2005, 46:1199–1206.PubMedCrossRef 20. Serhan CN: Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators.